Overview

Ranolazine Mediated PVC Reduction in Ischemic Heart Disease

Status:
Completed
Trial end date:
2018-02-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether ranolazine has beneficial effects on cardiac ischemia through reduction of premature ventricular contraction burden.
Phase:
Phase 2
Details
Lead Sponsor:
Kent Hospital, Rhode Island
Collaborator:
Gilead Sciences
Treatments:
Ranolazine